|
Found 8 result(s) FROM 1963 pages containing the term 'narcotics'.
Thursday Apr 02, 2009
Back Pain: Too Little Exercise, Too Much Imaging
Patients with low back pain are using too many ineffective treatments and too few of those proven effective...
Monday Oct 29, 2007
Research Shows Why Fibromyalgia Patients Don't Find Relief From Opioids
Fibromyalgia patients have abnormal functioning in a brain receptor involved in response to opioids, which may explain why they may not receive pain relief from narcotics or may require unusually high doses...
Friday Apr 13, 2007
Better Pain Management Urged for OA Patients Awaiting Hip or Knee Replacement in U.K.
Most patients on waiting lists for hip or knee replacement in Britain, report continuing, severe pain and suboptimal levels of analgesia...
Wednesday Mar 01, 2006
Effects of IV Steroids for Treatment of Acute Sciatica Are Transient
Intravenous steroids reduce pain in patients with severe acute discogenic sciatica, although the improvement is small and transient... Finckh A, et al. Spine. 2006;31:377-381.
Friday Sep 23, 2005
FDA Issues "Non-Approvable Letter" for Pfizer's Injectable COX-2 Drug
Just 1 week after receiving a nonapprovable letter for their new osteoporosis drug lasofoxifene (Oporia), Pfizer Inc announced Tuesday that the Food and Drug Administration (FDA) has issued a nonapprovable letter for parecoxib sodium, an injectable COX-2 inhibitor used to treat acute pain in the postsurgical setting... Pfizer receives FDA non-approvable letter on parecoxib [press release]. PR Newswire; September 20, 2005.
Monday Jul 25, 2005
Government Crackdown on Palladone and Fentanyl Continues to Fuel Fear of Prescribing Pain Medication
Withdrawal of Palladone in the US, the advisory report issued on the fentanyl patch, and the continued DEA scrutiny of doctors who prescribe opioids and other narcotic analgesics may have a chilling effect on the optimal use of these agents for the relief of acute and persistent pain.
Thursday Apr 07, 2005
FDA Orders Valdecoxib (Bextra) Withdrawn, Citing No Added Advantage
The agency also mandated black box warnings for celecoxib and stricter label warnings on traditional NSAIDs, including over-the-counter products... US Food and Drug Administration teleconference April 7, 2005.
Tuesday Aug 31, 2004
Primary Care Physician Survey Shows Back Pain Highly Prevalent, Often Involves Spasm
Acute back injuries often have a spasmodic as well as an inflammatory component; treating both expedites recovery.
|
